Reforming the payment system for medical oncology

JAMA. 2013 Jul 17;310(3):261-2. doi: 10.1001/jama.2013.8127.
No abstract available

MeSH terms

  • Antineoplastic Agents / economics
  • Drug Costs*
  • Drug Discovery
  • Drug Industry
  • Episode of Care
  • Fees and Charges*
  • Guideline Adherence
  • Humans
  • Lobbying
  • Medical Oncology / economics*
  • Medicare / economics
  • Physicians / economics
  • Reimbursement Mechanisms / economics*
  • United States

Substances

  • Antineoplastic Agents